US 12,202,856 B2
Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
Youssef Jounaidi, Boston, MA (US); Stuart Forman, Arlington, MA (US); Keith Miller, Lincoln, MA (US); and Joseph F. Cotten, Northborough, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Appl. No. 16/302,001
Filed by The General Hospital Corporation, Boston, MA (US)
PCT Filed May 19, 2017, PCT No. PCT/US2017/033585
§ 371(c)(1), (2) Date Nov. 15, 2018,
PCT Pub. No. WO2017/201432, PCT Pub. Date Nov. 23, 2017.
Claims priority of provisional application 62/471,456, filed on Mar. 15, 2017.
Claims priority of provisional application 62/338,757, filed on May 19, 2016.
Prior Publication US 2020/0316118 A1, Oct. 8, 2020
Int. Cl. C07K 16/46 (2006.01); A61K 39/00 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/00 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 39/4613 (2023.05); A61K 39/464406 (2023.05); A61K 39/464493 (2023.05); C07K 14/70521 (2013.01); C07K 14/7155 (2013.01); C12N 5/0646 (2013.01); A61K 9/0019 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05); A61K 2239/58 (2023.05); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)] 7 Claims
 
1. A fusion protein comprising interleukin 2 (IL2) fused to the N-terminus of full-length interleukin 2 receptor beta (IL2Rβ) without a signal peptide, with an intervening linker comprising an extracellular domain of IL2Rα, and a cytoplasmic domain of interleukin 21 receptor (IL21R) at the C-terminus of IL2Rβ, optionally with an intervening linker therebetween.